Armstrong, A. E., Rhodes, S. D., Smith, A., Chen, S., Bessler, W., Ferguson, M. J., . . . Clapp, D. W. (2020). Early Administration of Imatinib Mesylate Reduces Plexiform Neurofibroma Tumor Burden with Durable Results after Drug Discontinuation in a Mouse Model of Neurofibromatosis Type 1. Pediatr Blood Cancer.
Chicago Style citaatArmstrong, Amy E., et al. "Early Administration of Imatinib Mesylate Reduces Plexiform Neurofibroma Tumor Burden With Durable Results After Drug Discontinuation in a Mouse Model of Neurofibromatosis Type 1." Pediatr Blood Cancer 2020.
MLA citatieArmstrong, Amy E., et al. "Early Administration of Imatinib Mesylate Reduces Plexiform Neurofibroma Tumor Burden With Durable Results After Drug Discontinuation in a Mouse Model of Neurofibromatosis Type 1." Pediatr Blood Cancer 2020.